Roundtable Discussion: Diving Deep into the Modality Matrix to Determine the Optimal Approach for Immune Resetting
- Matching the modality to the pathogenic cell subset driving the disease
- Comparing the logistical and risk profiles of different classes of therapies and defining an acceptable risk-benefit ratio for large autoimmune patient populations
- Exploring the potential for combination therapies pairing a single dose reset agent with a subsequent maintenance modality to enhance durability and reduce relapse risk